New Colombia Resources Inc fka NEWC

[quipu]

NEWC - The way of Cannabis .............

New Colombia Resources, Inc.

www.newcolombiaresources.com
http://www.secinfo.com/$/SEC/Registrant.asp?CIK=772370
http://www.dinero.com/edicion-impresa/negocios/articulo/medicamentos-legales-derivados-del-cannabis-marihuana/199474
http://www.linkedin.com/pub/john-campo/28/525/780
http://www.sannabis.co/
https://es-es.facebook.com/sannabis.cannamedicinal
http://www.phoenixtearsfoundation.com/
http://www.medicaljane.com/

http://cannabissativa.co/companies/new-colombia-resources-inc


New Colombia Resources Inc. subsidiary, Sannabis SAS, Announces Product Line of Medical Marijuana Based Products in Colombia
BOGOTA, Colombia, Nov. 12, 2014 /PRNewswire/ --
New Colombia Resources, Inc. (OTCQB: NEWC) ("New Colombia or the Company"), a U.S. company with coal and other resource assets in Colombia, through its subsidiary Sannabis S.A.S. ("Sannabis"), is pleased to add details about their Colombian hemp and cannabis business. Sannabis legally produces Cannabis based products manufactured on the TOEZ Indian Reservation in Colombia where they have gained political and media support for their innovative efforts. Sannabis and New Colombia Resources will host a Senate delegation at their facilities on the TOEZ Reservation in the coming months. A media event for the inauguration of their new installations will be hosted when build out is completed in the next 30 – 60 days. The inauguration of the new production and sales facility will follow indigenous cultural protocols.
Dr. Bob Melamede, scientific advisor to New Colombia, has a Ph.D. in Molecular Biology and Biochemistry from the City University of New York, he retired as Chairman of the Biology Department at University of Colorado, Colorado Springs in 2005, where he taught and researched cannabinoids, cancer, and DNA repair until earlier this year. He is assisting the company in building a team of world-renowned experts. Dr. Melamede, President Emeritus of Cannabis Science Inc. (CBIS), has written many articles on the body's Endocannabinoid System and its reaction to CBD's.
Sannabis S.A.S. is a 50/50 joint venture between New Colombia Resources and others, including members of the TOEZ Reservation. Sannabis is a commercial and social initiative with first mover advantage that is creating a new Hemp and Cannabis Industry in Colombia. Sannabis is documenting patients for eventual FDA and INVIMA application of a pharmaceutical product. Sannabis is operating under Colombian Government regulation based on INVIMA concept of favorable Sentence C-176 of 1994 and Colombia's Constitutional Court Resolution C-882 of 2011.
"Our goal is to grow industrial fiber hemp on our green fields atop our underground mining operations in Guaduas," stated John Campo, President of New Colombia Resources. Sannabis will work with their indigenous partners to establish a sustainable hemp industry on Indian Reservations in Colombia.
Sannabis projects their products will have 50% gross margins based on wholesale sales to distributors in Colombia and neighboring countries where export sales are allowed. They also plan to sell direct to patients at higher direct to consumer margins. Sannabis has been producing therapeutic medicines on the TOEZ reservation for over 2 years. Their current product line includes: Pure essential oil extracted from cannabis flower with steam and pure extracted cannabis flower resin. Pain Relief cream, for external use only, with essential extracts of sacred plants such as eucalyptus, pine, castor, ortiga, Nettle, tobacco, and cannabis flower. Scar and Wound Cream, for external use only, with a mixture of almond oils and cannabis seeds (omega 3, 6 and 9) with the power of medicinal plants like calendula, chamomile, and cannabis flower. Massage Oil made from an aromatic blend of almond oil and essential extracts from rosemary and cannabis flower.
Resina puraFollow Sannabis on Facebook at https://www.facebook.com/sannabis.cannamedicinal
Their new website, www.sannabis.co will be operational soon.
http://www.prnewswire.com/news-releases/new-colombia-resources-inc-subsidiary-sannabis-sas-announces-product-line-of-medical-marijuana-based-products-in-colombia-282396571.html

Medical Marijuana Clinical Trials Creating New Opportunities for Producing Therapeutic Medicines for Future FDA & INVIMA Applications
CORAL SPRINGS, Florida, November 5, 2014 /PRNewswire/ --
Cannabis industry forecasts billions in revenue as United States moves towards legalization and MMJ Companies focus on new plans, joint ventures and development of innovative Marijuana products. Companies in Focus Today are: New Colombia Resources, Inc. (OTCQB: NEWC), Neutra Corp. (OTC: NTRR), Creative Edge Nutrition, Inc. (OTC: FITX), Tauriga Sciences, Inc. (OTC: TAUG) and Cannabis Science, Inc. (OTC: CBIS).
New Colombia Resources, Inc. (OTCQB: NEWC) ("New Colombia or the Company"), a U.S. company with coal and other resource assets in Colombia, is pleased to announce plans to spin out its Sannabis S.A.S medical hemp based products company and create an independent U.S. traded reporting publicly traded company. John Campo, President, stated: "Our management team is focused on our core business of developing company coal reserves and industrial aggregate operations. By allowing Sannabis SAS to become an independent public company it will be able to develop its own medical based management team. Additionally Sannabis will have one mission the development of its innovative medical products based on scientific research using unique strains of Cannabis manufactured on the TOEZ Indian Reservation in Colombia. The Company plans to issue shares of Sannabis S.A.S. as a dividend to Shareholders.
After the spinoff Sannabis S.A.S. will operate as an independent company and develop its own medical research staff and funding to further the commercialization of its products. Sannabis S.A.S. aims to become the first company to legally import hemp and medical marijuana products to the U.S. from Colombia. Operations will include patent applications, obtaining medical approvals, and further research and product development. Sannabis SAS believes that the specific strain of hemp being produced on the TOEZ Indian reservation may creates a unique medical opportunity for many people who may find benefit from various hemp based product derivates.
Neutra Corp. (OTCQB: NTRR) recently announced it is finalizing plans for its first commercial production run of the cutting-edge Diamond Anvil Vapor Pen just as analysts are predicting the cannabis industry will not only be legal, but have more annual revenue than the NFL by 2020. Greenwave Advisors, a cannabis-focused research and analysis firm, recently projected federal legalization of the herb in the next six years, which would push first-year countrywide revenues to an estimated $35 billion, surpassing the annual revenue of the NFL. Even without full federal legalization, Greenwave still projects $21 billion in legal cannabis revenues, however, the firm believes 12 states and the District of Columbia will have legalized recreational cannabis by 2020, with medical cannabis being available in 37 states. Currently 23 states have legalized medical cannabis and two states have legalized recreational cannabis use.
Creative Edge Nutrition, Inc. (OTCPink: FITX), a nutritional supplement company, develops, markets, and sells nutraceuticals and health supplements. It offers a range of capsules, tablets, and powders, as well as science based products in weight management, specific nutrition challenges, energy, and fitness categories. The company's products comprise HYPER INFUSION, a pre work-out catalyst; AMINO PLEX, a intra-workout recovery catalyst; CENTRO PLEX, an advanced meal replacement product; ALPHA DRIVE to enhance free testosterone levels; VASOBOLIC, a stimulant free nitric oxide pre-cursor; INOVA, a pre-workout supplement; REDEMPTION; FREE REIGN to increase free testosterone; ROGUE, a muscle builder; THYROZINE, a mood elevating thermogenic; HYPE, a high intensity thermogenic; and REGIME, a physique enhancement product. It also provides natural products, such as Hemp Nutra tea, coffee additives, and slimming tea. On Tuesday, FITX closed up 2.7% on over 19.1 million shares traded.
Tauriga Sciences, Inc. (OTCQB: TAUG), a diversified life sciences company with interests in the natural wellness sector and in developing a proprietary synthetic biology platform technology, announced that it has signed a non-binding MOU with Japan-based iFlow, Ltd. ("iFlow") to distribute and sell three new Tauriga-branded natural wellness products to the Japan, Taiwan and Hong Kong regions (the "Territory"). iFlow is an innovative and entrepreneurial Asian marketing and distribution company with motivational products in health, lifestyle, education, business and finance. If a definitive agreement is reached, the partnership between the companies would enable Tauriga to reach Asian customers with an interest in natural healing. The intent of the parties is for the initial focus of the partnership to be on two different formulations of Tauriga's proprietary TopiCanna topical cannabis cream and on Tauriga's CannaCaviar brand of small soft gel supplements. In compliance with Japanese medical marijuana law, all three products would use oil that has been extracted from the stalk of the cannabis plant and that is higher in CBD (cannabidiol) and low in THC, hence providing wellness and healing properties without psychoactive effects. If the initial phase of the proposed partnership is successful in establishing the Tauriga natural wellness brand in the Territory, the two companies plan to extend the agreement to include additional Tauriga products, such as Tauriga's new line of natural dietary supplements.
Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting is very pleased with the laboratory analytical reports it recently received. The testing of the cannabis harvested using EU certified as well as its own unique strains produced end results indicating that whole extracts to be produced will contain upward of 20% CBD and less than 10% THC. Furthermore, other unique identifiers are present that require multiple authentications based on their significant nature. These numbers are significant based on usage information and expected treatment regimes for many of the Company targeted ailments. The Company continues investigating both its unique cannabinoid strains as well as promising strains from around the world for multiple pre-clinical drug development programs targeting Cancer, Neurological Disorders, and a few other targeted critical ailments to be announced.
http://www.digitaljournal.com/pr/2310497

New Colombia Resources Inc. Plans Spin Off of its Colombia Medical Marijuana Products Company
The Company plans to issue shares of Sannabis S.A.S. as a dividend to Shareholders.
Bogotá , Colombia November 5, 2014 –
New Colombia Resources, Inc. (OTCQB: NEWC) (“New Colombia or the Company”), a U.S. company with coal and other resource assets in Colombia, is pleased to announce plans to spin out its Sannabis S.A.S medical hemp based products company and create an independent U.S. traded reporting publicly traded company.

John Campo, President stated “Our management team is focused on our core business of developing company coal reserves and industrial aggregate operations. By allowing Sannabis SAS to become an independent public company it will be able to develop its own medical based management team. Additionally Sannabis will have one mission the development of its innovative medical products based on scientific research using unique strains of Cannabis manufactured on the TOEZ Indian Reservation in Colombia.

New Colombia Resources, Inc. operations are based on the acquisition and development of high-quality metallurgical coal properties and other available resources in the Republic of Colombia. New Colombia owns 100% of La Tabaquera metallurgical coal mine in Colombia with an estimated 15- 17 million metric tons of reserves as well as a vast supply of industrial aggregates required in road building and construction. Upon property evaluation and finalization of funding, the company plans two mining property acquisitions that include a 1500 ha and 390 ha metallurgical coal concession that have the potential to more than triple company coal assets.

After the spinoff Sannabis S.A.S. will operate as an independent company and develop its own medical research staff and funding to further the commercialization of its products. Sannabis S.A.S. aims to become the first company to legally import hemp and medical marijuana products to the U.S. from Colombia. Operations will include patent applications, obtaining medical approvals, and further research and product development. Sannabis SAS believes that the specific strain of hemp being produced on the TOEZ Indisan reservation may creates a unique medical opportunity for many people who may find benefit from various hemp based product derivates.
http://www.financialnewsmedia.com/profiles/newc.html

New Colombia Resources Inc Subsidiary, Sannabis, Produces First Batch of Medical Marijuana Based Products in Colombia to Fill Back Orders.
Sannabis is producing a "Made in Colombia" topical cannabis medical product for worldwide distribution through infomercials.
BOGOTA, Colombia, Oct. 24, 2014 /PRNewswire/ --
New Colombia Resources, Inc. (NEWC) ("New Colombia or the Company"), a U.S. company with coal and other resource assets in Colombia, is pleased to announce their Colombian subsidiary, Sannabis S.A.S., has legally produced a trial run of cannabis based products on an Indian reservation. The Sannabis brand is a registered trademark of Sannabis S.A.S., a joint venture between New Colombia Resources and Juan Paolo Guzman with members of the TOEZ Indian Reservation in Caloto, Norte del Cauca, a region known for the most sought after medicinal Cannabis strains in the world.
Members of the tribe in association with Mr. Guzman have been producing the Sannabis brand of cannabis based medical products for over 2 years. Mr. Guzman is a respected member of the Colombian Medical Cannabis Community for over 20 years, spearheading a movement to medically accept Cannabis in Colombia that has little opposition.
Follow Sannabis on Facebook at https://www.facebook.com/sannabis.cannamedicinal.
Their new website, www.sannabis.co will be operational soon.
New Colombia Resources is very pleased to work with the TOEZ tribe to bring these life improving products to market. Last week Sannabis produced over 700 topical products to distribute to patients in despair. Sannabis is setting up a pharmaceutical grade production line on the TOEZ reservation. They are bringing U.S. technology to this growing sector, first by purchasing machinery to make essential oils and resins which are manufactured into therapeutic medicines on the Reservation, then by documenting patients for eventual FDA or INVIMA approval of a pharmaceutical product.
Sannabis has been overwhelmed by the interest of potential distributors in all parts of Colombia. They have back orders that need to be filled. Sannabis is producing a "Made in Colombia" topical cannabis medical product for worldwide distribution through infomercials. Sannabis will continue to legally produce over the counter natural therapeutic products while following protocols to develop a pharmaceutical product.
New Colombia Resources and Sannabis were invited by Senator Juan Manuel Galan to attend a forum yesterday in the Colombian Senate titled "Use of Medical Marijuana: From Myth to Evidence." Panelists included representatives from the Ministry of Justice, Ministry of Health, Drug Agency, Universities, and others. All of the participants gave passionate opinions in favor of regulating medical marijuana as a legitimate medicine. One went as far as to suggest a new "National Cannabis Agency."
The final and most meaningful comments came from the mother of Jacobo, a 3 year old boy with Epilepsy, who said no matter what the regulators say or do, her "duty as a mother comes first." Like many children around the world with epilepsy, daily seizures along with prescribed medications that weren't working, prevented Jacobo from enjoying his childhood. A cannabis based medicine has allowed him to live a happier seizure free life.
Sannabis has developed a high CBD, low THC medicine for children with Dravet Syndrome. Some of their patients have avoided moving to Colorado because of Sannabis; other parents can't afford their products. Sannabis is developing a program for willing parents that can afford the medicine to subsidize those that can't.
"I'm ecstatic about bringing a team of experts from the U.S. and Canada to help Indian reservations develop sustainable hemp and cannabis industries, all while helping patients that before had no hope. Just like the mining industry, there are ideal conditions and a low cost of production. In Colombia the market for medical products in general is growing by the minute. It's a perfect time to market new therapeutic products, especially when they work like no other," stated John Campo, President of New Colombia Resources Inc.
Additionally, New Colombia expects approval of their environmental permit within days. As soon as the permit is approved they will begin to move material. The Company will issue a more detailed release on their mining operations at a later date.
http://finance.yahoo.com/news/colombia-resources-inc-subsidiary-sannabis-120000886.html

New Colombia creates joint venture to produce cannabis and hemp based medicinal products
Published on October 9, 2014 at 9:22 AM
New Colombia Resources, Inc. (OTCQB: NEWC) ("New Colombia or the Company"), a U.S. company with coal and other resource assets in Colombia, is pleased to announce they have formed a joint venture to produce cannabis and hemp based medicinal products in Colombia in association with an indigenous community in Colombia. All of the products are produced on the indigenous reservation and commercialized under the favorable sentence C-176 of 1994 and C-882 of 2011 of the constitutional court. Constitutional Court Resolution 010 of 2013 gives territorial entities, such as indigenous reservations, the right to "govern themselves by proper authority."
Cannabis and hemp based products have been produced and sold by indigenous people in all parts of Colombia for many years. New Colombia's partner in this venture has been producing these products on indigenous reservations with miraculous results. They have many testimonials from patients who are using these products. They have topical products that treat, cancer, arthritis, and fibromyalgia. The partnership will focus strongly on producing an exceptional strain for Dravet Syndrome, much like Charlotte's Web. In addition to treating paying patients, New Colombia and its partners will form a foundation to treat underprivileged children with Dravet Syndrome and others.
New Colombia Resources will identify the indigenous community and their brand once the proper legal framework has been established. The company has received a tremendous amount of support from law makers in Colombia. Company President, John Campo, was invited on live television by a conservative senator to make a presentation in front of the Colombian Senate. Mr. Campo is documenting cases of patients that have been cured or relieved by cannabis based products produced on indigenous reservations.
Additionally, New Colombia is actively preparing their property for mining operations. They are in discussions with investment bankers to finance their coal operations. The Company is building two trailers for their rock crushing plant for added mobility and value while they await approval of their environmental permit. As soon as the permit is approved they will begin to sell material. The Company will issue a more detailed release on their mining operations.
http://www.news-medical.net/news/20141009/New-Colombia-creates-joint-venture-to-produce-cannabis-and-hemp-based-medicinal-products.aspx

New Colombia Resources Inc. Provides Update to Shareholders
BOGOTÁ, Colombia / ACCESSWIRE / August 19, 2014
New Colombia Resources, Inc. (OTCQB: NEWC) ("New Colombia or the Company"), a U.S. company with coal and other resource assets in Colombia, is pleased to update shareholders on the progress of their mining operations. As previously announced, New Colombia will develop a 1000 m3 per day rock quarry on their property while they bring coal operations online. The company originally expected to start quarry operations earlier this year, due to issues with a land purchase agreement, and a pending site visit, the initiation has been delayed for a few weeks.
The company received notice from the local environmental authority of a site visit for September 13, 2014. New Colombia Resources believes it is in their best interest to begin gravel operations after this inspection. They expect this visit to be the final step in the approval of their coal mining permit. The company's Work Plan (PTO) was approved on December 23, 2013. Their environmental impact plan has been under review for several months; the company believes their coal mining permit will be issued soon after the visit.
New Colombia's subsidiary, Compañía Minera San Jose Ltda., has fully paid and executed a land purchase agreement that transferred title on August 15, 2014. The company's President made a capital injection of $ 50,000 into New Colombia Resources on July 25, 2014 to facilitate this transaction. Mr. Campo will enter into a royalty agreement with the Company which will be disclosed once finalized.
In addition to the purchased greenfield, New Colombia is leasing property along national highway I-50 leading to Bogota to use as a rock depot. The processed aggregates will be trucked down from their mine using existing haul roads to the highway. From there the material will be trucked in bigger dumpers to end users. The municipality of Guaduas is finishing construction of a haul road that leads down to Colombia's largest new highway, Ruta del Sol, from their mine in 6 Km. In addition to Highway I-50, New Colombia will lease or purchase a rock yard along the new Road to the Sun.
New Colombia Resources purchased a rock crushing plant capable of producing over 100 m3 per hour. Although they received a letter of intent to purchase over 600 m3 per day in Bogota, they will pursue the closest buyer to optimize profit margins by reducing transportation costs. The company will be finalizing purchase agreements for their building materials as they get closer to production. They are materializing an operator's agreement with a third party operator of excavation equipment and dump trucks.
New Colombia Resources is featured in a print article in the current edition of Dinero Magazine, Colombia's leading financial news publication. The article focused on New Colombia's initiative to develop the first legal cannabis based pharmaceutical product in Colombia while initiating their coal operations. To view the article visit http://www.dinero.com/edicion-impresa/negocios/articulo/medicamentos-legales-derivados-del-cannabis-marihuana/199474
http://online.wsj.com/article/PR-CO-20140819-907371.html#

Hemp Based Products Grow in Popularity as R&D Studies Reveal Progress - NEWC Announces Results for Recent Market Study
CORAL SPRINGS, Florida, June 3, 2014 /PRNewswire/ --
Cannabis companies making progress by forging ahead with product developments, Hemp based product studies and form business partnerships as the industry expands: New Colombia Resources, Inc. NEWC, +16.83% Cannabis Science, Inc. CBIS, +5.60% Tranzbyte Corporation ERBB, +0.00% Nuvilex, Inc. NVLX, -3.25% and Hemp, Inc. HEMP, -2.56%
New Colombia Resources, Inc. (otcqb:NEWC) is pleased to announce results of a market study by leading Hispanic infomercial producer, Doral Studios, of hemp based products for the U.S. Hispanic and Latin American markets. Doral Studios Inc. d/b/a RC Television Production has produced English and Spanish speaking infomercials for over 15 years. Their market research team did a survey to gauge the interest between in a pain or beauty hemp based product for the Hispanic market. The results were very favorable for these innovative new products. The following are basic conclusions of the consumer preference analysis done by Doral Studios Inc. in reference to the products.
To Read the Full NEWC Press Release, go to: http://fnmprofiles.com/profiles-newc.html
The population subject of the study included male and female professionals, makeup artists, personal trainers, corporate executives, students, housewives, and others. The age brackets were calculated every ten years, except for the first segment that was from age 25 to 40. Based on the data results of the overall survey, RC Television Productions considers the direction for the placement of the product is the PAIN REDUCING CREAM. The enhancement of the product with its hemp content had a very positive impact on consumers; especially due to the wide spread knowledge of the medicinal uses of hemp and cannabis. This represents a very powerful marketing tool, with consumer awareness and a tremendous marketing advantage at the present time. Timing is of the essence to convert the brand and the product into a market leader.
Cannabis Science, Inc. CBIS, +5.60% a U.S. Company specializing in the development of cannabis based medicine, announced that the first set of data from the preclinical development of proprietary cannabinoid-based product is expected this week. The product development for neurological disorders is one of the many applications the Company is developing under the patent filed last year. In response to the numerous communications that the Company receives from the general public about medical cannabis research and treatment for critical ailments, Cannabis Science intends to establish an informational hotline in the near future to respond in real time to questions and to provide educational information about cannabinoid-based products. To Read the Full CBIS Press Release, go to: http://finance.yahoo.com/news/cannabis-science-operational-first-data-131500829.html
Tranzbyte Corporation (otc pink:ERBB) recently announced that it has selected SmarterSign to deliver ads to the top screen of its ZaZZZ units. The platform offers a scalable solution combined with ease of use that works perfectly withAmerican Green's integrated advertising plan allowing the store, local, and national advertisers to control messaging in real-time from anywhere in the world. The company also announced the addition of Urban Cannabist to its suite of web properties. Urban Cannabist is a dispensary locator designed to work on all computer and cell phone screens and will evolve into a social rating application as a fully integrated part of its growing web presence.
Nuvilex, Inc. (otcqb:NVLX) recently announced it now has access to $50 million with a new banking agreement. In an original funding agreement that was not favorable at all to the company's shareholders, Nuvilex had access to $27 million, but with a new at-the-market banking agreement with Chardan Capital, the company now has access up to $50,000,000 which is $23 million more than it had access to just one week ago. This new at-the-market banking agreement with Chardan will give the Maryland biotech access up to $50,000,000, the opportunity to get out of a "not-so-friendly" deal with another firm, and it will help the company to preserve shareholder value by allowing it to control the deal. This is an agreement that should put Nuvilex in a very comfortable place and let it get to work on furthering its treatment for advanced pancreatic cancer and diabetes using the company's Cell-in-a-Box® technology.
Hemp, Inc.'s (otc pink:HEMP) wholly owned subsidiary, The Industrial Hemp and Medical Marijuana Consulting Company, Inc. (IHMMCC), recently announced that it has signed a consultant agreement with View Systems, Inc. VSYM, +16.50% a leading Baltimore-based manufacturer and provider of integrated weapons detection systems. Per the agreement, IHMMCC will provide product distribution, professional sales and marketing services, and sales representation for the View-Scan product line to the Industrial Hemp and Medical Marijuana Industries, as well as other traditional channels of distribution. The Agreement apportions 480 View-Scan units to be sold in the marketplace. Areas of initial interest include Colorado, Washington, California, Arizona and Nevada, but IHMMCC expects to expand beyond these areas. IHMMCC has already begun marketing the View-Scan unit at the first annual Cannabis Capital Summit and HempZone lounge, in Denver, Colorado, where View Systems, Inc. (VSYM) was able to showcase its product line in front of hundreds of potential buyers and investors in the cannabis industry.
http://www.marketwatch.com/story/hemp-based-products-grow-in-popularity-as-rd-studies-reveal-progress-newc-announces-results-for-recent-market-study-2014-06-03

New Colombia Resources Inc Announces Results of a Market Survey of Hemp Based Products for the U.S. and Latin American Markets
MIAMI BEACH, Fla., June 3, 2014 /PRNewswire/ --
New Colombia Resources, Inc. (NEWC) ("New Colombia or the Company"), a U.S. company with coal and other resource assets in Colombia, is pleased to announce results of a market study by leading Hispanic infomercial producer, Doral Studios, of hemp based products for the U.S. Hispanic and Latin American markets.
Doral Studios Inc. d/b/a RC Television Production has produced English and Spanish speaking infomercials for over 15 years. Their market research team did a survey to gauge the interest between in a pain or beauty hemp based product for the Hispanic market. The results were very favorable for these innovative new products. The following are basic conclusions of the consumer preference analysis done by Doral Studios Inc. in reference to the products.
The population subject of the study included male and female professionals, makeup artists, personal trainers, corporate executives, students, housewives, and others. The age brackets were calculated every ten years, except for the first segment that was from age 25 to 40.
Questions during the Consumer Preference Segment:
Would you buy a beauty enhancing product? The product would help with stretch marks, scars, crow's feet, wrinkles, etc, leaving a clear and soft skin with a 10 year younger look.
Would you buy a pain reducing product? The product would act on rheumatism, arthritis, and muscle pain due to exercise, accidents or any kind of pain induced by illness.
After the selection was made, the hemp or cannabis content of the product was disclosed and the reinforcement of the decision was made as to the consumer preference.
RESULTS
The participants that selected the pain reducing cream reinforced their decision to purchase the product in 99% of the cases. Only one rejected the use of the product in either cream due to hemp or cannabis content.
For the participants that selected the Beauty cream, only 2 out of 6 would reconsider changing their decision and purchase the pain reducing cream once they were informed it was hemp or cannabis based. These participants disclosed that that they would prefer to use Doctor indicated alternatives in reference to pain reducing options.
Age 25 -40 41- 50 51- 60 61 +
Pain Reducing Cream 52% 13% 17% 17%
Beauty Enhancing Cream 29% 58% 0% 14%
CONCLUSION
Based on the data results of the overall survey, RC Television Productions considers the direction for the placement of the product is the PAIN REDUCING CREAM. The enhancement of the product with its hemp content had a very positive impact on consumers; especially due to the wide spread knowledge of the medicinal uses of hemp and cannabis. This represents a very powerful marketing tool, with consumer awareness and a tremendous marketing advantage at the present time. Timing is of the essence to convert the brand and the product into a market leader.
New Colombia Resources will work with their scientific advisor, Dr. Robert Melamede PhD, President Emeritus of Cannabis Science, Inc. (CBIS) to produce an effective product to brand and target to the Latin American and U.S. market. "We look forward to educating people on the many medicinal benefits of cannabis and hemp through infomercials, "stated John Campo, President of New Colombia Resources, Inc.
New Colombia is putting together a business plan for investors to manufacture the products, produce the infomercial, and purchase airtime throughout the U.S. and Latin America. For more information on RC Television Productions visit http://www.rctelevision.com.
http://finance.yahoo.com/news/colombia-resources-inc-announces-results-120000912.html

Clinical Studies for Cannabis Based Drug Development Targets Multitude of Medical Treatments - CBIS Issues CBN Patent and R&D Guidance
CORAL SPRINGS, Florida, May 22, 2014 /PRNewswire/ --
Cannabis Industry making strides in developing new patents, therapy solutions and diversified products for medical patients: Cannabis Science, Inc. CBIS, +5.60% Medical Marijuana Inc. MJNA, -4.93% New Colombia Resources, Inc. NEWC, +16.83% GW Pharmaceuticals plc GWPH, -0.28% and Nuvilex, Inc. NVLX, -3.25%
Cannabis Science, Inc. CBIS, +5.60% a U.S. Company specializing in cannabis formulation-based drug development issues CBN patent and R&D guidance for the 2nd quarter of 2014 to its shareholders.
To support its existing CBN patent, the company has delivered pure CBN compound to two research facilities in Europe where testing will be started to establish activity of CBN alone and in combination with other cannabinoids in anxiety, sleep disorders as well as in variety of neurological conditions including Alzheimer's disease. Earlier this year the company has raised funds to facilitate Cannabis Science's R&D activities that will include production of pharmaceutical grade cannabis-based formulations to be developed for variety of illnesses, to continue moving forward its clinical observational studies and to initiate pre-clinical work on the Company's new product to address neurobehavioral disorders.
To read the full CBIS press release, please click here: http://finance.yahoo.com/news/cannabis-science-issues-cbn-patent-110000335.html
"Cannabis Science has made solid progress so far this year. I am proud to be a part of this team and I am very positive about our future," stated Robert Kane, CFO of Cannabis Science.
Medical Marijuana Inc. MJNA, -4.93% operates in the medical marijuana and industrial hemp markets. Its products range from patented and proprietary based cannabinoid products to seed and stalk or isolated high value extracts manufactured and formulated for the pharmaceutical, nutraceutical, and cosmeceutical industries. The company's services include development of cannabinoid based health and wellness products; and development of medical grade compounds; and licensing of proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal herb industry. On Wednesday, MJNA closed up .82% on over 4.7 million shares traded.
New Colombia Resources, Inc. (otcqb:NEWC), a U.S. company with coal and other resource assets in Colombia, recently announced the engagement of Doral Studios for a market study of hemp based products in the U.S. and Latin American markets. Once the study is concluded, the Company will decide what type of product to market, either a pain or beauty product. Doral Studios Inc. d/b/a RC Television Production has been producing English and Spanish speaking infomercials and music videos for over 15 years. They have a state of the art production studio in Doral, FL where they have produced the most successful Spanish language infomercials on the air in the U.S. and Latin America. They handle every aspect of an infomercial including: concept, logo, animation, graphics, passive and aggressive CTA (Call to Action), and high definition production. They work with focus groups to determine the direction of the product or idea. Doral Studios has long standing relationships with the biggest Spanish language broadcasters in the world. To read the full NEWC press release, please click here: http://finance.yahoo.com/news/colombia-resources-inc-engages-infomercial-123000777.html
GW Pharmaceuticals plc GWPH, -0.28% a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform, recently announced that the Company has received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug application (IND) is now open for Epidiolex in the treatment of Dravet Syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. GW expects to commence a Phase 2/3 clinical trial in the second half of 2014. Epidiolex has already received orphan drug designation from the FDA for the treatment of Dravet syndrome. "The acceptance of this IND by the FDA is a significant milestone for Epidiolex and for children with Dravet syndrome for whom existing anti-epileptic medicines often do not provide adequate relief," stated Justin Gover, GW's Chief Executive Officer.
Nuvilex, Inc. (otcqb:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, recently announced that, together with Translational Drug Development (TD2) in Scottsdale, Arizona, preparations have begun for US-based preclinical and then clinical studies on the unbearable pain and the accumulation of fluid in the abdominal cavity which are two commonly occurring symptoms associated with advanced pancreatic cancer. TD2 will study the effectiveness of Nuvilex's pancreatic cancer treatment in relieving the unbearable pain and the accumulation of abdominal fluid known as "ascites." Nuvilex's pancreatic cancer treatment, which combines the Cell-in-a-Box[(R)] live-cell encapsulation technology with the well-known anticancer drug ifosfamide, will be studied with the expectation that it can improve the quality of life of pancreatic cancer patients by relieving these two chronic symptoms usually associated with the development of advanced pancreatic cancer. The preclinical studies are being planned to commence shortly and, if successful, they will be soon followed by clinical trials in both pain severity and ascites accumulation.
http://www.marketwatch.com/story/clinical-studies-for-cannabis-based-drug-development-targets-multitude-of-medical-treatments-cbis-issues-cbn-patent-and-rd-guidance-2014-05-22

New Colombia Resources, Inc. Engages an Infomercial Company for Market Analysis of Hemp Based Products for the U.S. Hispanic and Latin American Markets
MIAMI BEACH, Fla., May 22, 2014 /PRNewswire/ --
New Colombia Resources, Inc. (NEWC) ("New Colombia or the Company"), a U.S. company with coal and other resource assets in Colombia, is pleased to announce the engagement of Doral Studios for a market study of hemp based products in the U.S. and Latin American markets. Once the study is concluded, the Company will decide what type of product to market, either a pain or beauty product.
Doral Studios Inc. d/b/a RC Television Production has been producing English and Spanish speaking infomercials and music videos for over 15 years. They have a state of the art production studio in Doral, FL where they have produced the most successful Spanish language infomercials on the air in the U.S. and Latin America. They handle every aspect of an infomercial including: concept, logo, animation, graphics, passive and aggressive CTA (Call to Action), and high definition production. They work with focus groups to determine the direction of the product or idea. Doral Studios has long standing relationships with the biggest Spanish language broadcasters in the world. They work with telemarketing associates to handle incoming calls. To view Doral Studios demos visit http://www.youtube.com/results?search_query=doral+studios
Once Doral Studios determines which product they feel will have the best results, New Colombia Resources will work with their scientific advisor, Dr. Robert Melamede PhD, and their pharmaceutical partner to manufacture the product. Doral Studios will help develop the brand.
http://finance.yahoo.com/news/colombia-resources-inc-engages-infomercial-123000777.html

Innovation Fuels New Cannabis Based Skin Care Medicines - NEWC's Pharmaceutical Partner in Discussions with City of Medellin
CORAL SPRINGS, Florida, May 20, 2014 /PRNewswire/ --
Medical Marijuana industry expansion continues as medical developments give way to new opportunities including Cannabis Based Skin Care Medicines: New Colombia Resources, Inc. (OTC: NEWC), Cannabis Science, Inc. (OTC: CBIS), Hemp, Inc. (OTC: HEMP), Nuvilex, Inc. (OTC: NVLX), and Tranzbyte Corporation (OTC: ERBB)
New Colombia Resources, Inc. (OTCQB: NEWC), a U.S. company with coal and other resource assets in Colombia, is pleased to announce they are in discussions with their pharmaceutical partner in Colombia to enter to an innovation program offered by the City of Medellín. The Ruta N organization was created to promote the development of innovative science and technology-based businesses in the city of Medellin, the winner in 2013 of the world's "Innovative City of Year" award by the Wall Street Journal and Citi.
New Colombia Resources' Medellin based pharmaceutical partner, Farmatech S.A., is meeting with Ruta N to establish the protocols needed to enter the program. Ruta N has created various projects and programs that articulate research and high-impact entrepreneurship by supporting innovative initiatives that have great potential in the global market. For more information on the Ruta N program visit http://rutanmedellin.org/index.php/en
To read the full press release, please click here:http://www.fnmprofiles.com/profiles-newc.html
New Colombia is in discussions with Cannabis Science Inc. (OTCQB: CBIS) to oversee this program along with their scientific advisor Dr. Robert Melamede, President of Cannabis Science Inc. (CBIS). "This program will benefit our efforts for approvals for research and development of legal cannabis based pharmaceutical products in Colombia," stated John Campo, President of New Colombia Resource, Inc.
Hemp, Inc. (OTC Pink: HEMP) announced today that it has purchased a whole line of automated Temafa decortication equipment designed to separate the fiber from the core of the hemp plant through a process known as decortication. The Temafa decortication line of equipment, the only one of its kind in the United States, purchased by Hemp, Inc. will now enable the company to process raw hemp for American farmers into two valuable base products (fiber and hurd) that can both yield hundreds of products. The equipment is currently located at a plant in North Carolina. Hemp, Inc. is set to move the equipment to a more suitable location such as Kentucky, Tennessee, South Carolina, North Carolina, or the Georgia area. "This purchase of decortication equipment was a critical step in order for Hemp, Inc. to help Americans transition from non-sustainable synthetic solutions to a hemp-based green solution. We are very excited at what we'll be able to achieve once our manufacturing facility ramps its hemp production volume up over the next few years," said Perlowin, CEO of Hemp, Inc.
Nuvilex, Inc. (OTCQB: NVLX) recently announced that it signed an agreement with the University of Northern Colorado to perform initial studies in the development of cancer treatments that combine the proprietary live-cell encapsulation technology Cell-in-a-Box® with constituents of cannabis known as cannabinoids. It was another quiet announcement that seemed to fly under the radar, and maybe purposely so, as Nuvilex is a biotechnology firm that wants to stay just that, but at the same time, the company wants to use all available tools to potentially improve its own cancer treatments and, in turn, potentially save lives. And that means medical marijuana needs to be an option given it has proven it has medicinal properties. So, in what has been Nuvilex's modus operandi over the last year or so, the company has sought out cannabis industry professionals in an attempt to position itself as a leader in medical marijuana. Unlike many companies that reside permanently in the cannabis space, putting out news daily with no substance and seemingly no end in sight to the claims, Nuvilex has methodically put together a world class Scientific Advisory Board (SAB) at its wholly owned subsidiary Medical Marijuana Sciences.
Tranzbyte Corporation (OTC Pink: ERBB) attracts established and early growth businesses seeking to take advantage of resources through the public capital markets and provides them capital, legal, accounting, and public relations resources. Tranzbyte recently announced that it will change its corporate name to AMERICAN GREEN™. The name change should be effective sometime within the next several weeks and is subject to review by FINRA and The State of Nevada. ERBB closed down on Monday (5/19/2014) at $0.021 on Heavy Volume Trading over 89 Million shares by the market close.
http://www.prnewswire.com/news-releases/innovation-fuels-new-cannabis-based-skin-care-medicines---newcs-pharmaceutical-partner-in-discussions-with-city-of-medellin-259933811.html

New Colombia Resources, Inc. to Enter an Innovation Program with the City of Medellin for Research and Development of Cannabis Based Products in Colombia
MIAMI BEACH, Fla., May 20, 2014 /PRNewswire/ --
New Colombia Resources, Inc. (OTCQB: NEWC) ("New Colombia or the Company"), a U.S. company with coal and other resource assets in Colombia, is pleased to announce they are in discussions with their pharmaceutical partner in Colombia to enter an innovation program offered by the City of Medellin. The Company will enter this program for the legal research and development of cannabis based medicines. The Ruta N organization was created to promote the development of innovative science and technology-based businesses in the city of Medellin, the winner in 2013 of the world's "Innovative City of Year" award by the Wall Street Journal and Citi.
New Colombia Resources' Medellin based pharmaceutical partner, Farmatech S.A., http://www.farmatech.com.co/ , is meeting with Ruta N to establish the protocols needed to enter the program. Ruta N has created various projects and programs that articulate research and high-impact entrepreneurship by supporting innovative initiatives that have great potential in the global market. For more information on the Ruta N program visit http://rutanmedellin.org/index.php/en.
New Colombia is in discussions with Cannabis Science Inc. (CBIS), http://www.cannabisscience.com/ , to oversee this program along with their scientific advisor Dr. Robert Melamede PhD, President of Cannabis Science Inc. (CBIS). "This program will benefit our efforts for approvals for legal research and development of cannabis based pharmaceutical products in Colombia," stated John Campo, President of New Colombia Resource, Inc.
http://article.wn.com/view/2014/05/20/New_Colombia_Resources_Inc_to_Enter_an_Innovation_Program_wi/

Cannabis Based Medicines Gain Traction as Research & Development Ramp up - Company Looks to Develop Topical Cannabis Medicine to Treat Skin Cancer
CORAL SPRINGS, Florida, May 15, 2014 /PRNewswire/ --
Marijuana industry displays versatility as companies diversify products by specializing in developing Cannabis Based medicines: New Colombia Resources, Inc. (OTC: NEWC), Easton Pharmaceuticals Inc. (OTC: EAPH), GW Pharmaceuticals plc (NASDAQ: GWPH), Medical Marijuana, Inc. (OTC: MJNA) and Terra Tech Corp. (OTC: TRTC)
New Colombia Resources, Inc. (OTCQB: NEWC), a U.S. company with coal and other resource assets in Colombia, is pleased to announce an agreement of collaboration with Farmatech S.A., of Medellin, Colombia, for the research and development of topical cannabis based medicines to treat skin cancer and other ailments in Colombia. Farmatech S.A. is a pharmaceutical laboratory that collaborates with private companies, universities, institutions, and NGOs. Their mission is to manufacture medicines as well as cosmetic and veterinary products, both proprietary and by contract. New Colombia Resources is in discussions with Cannabis Science, Inc. (OTCQB: CBIS) to oversee research in Colombia once the protocols are established by Farmatech S.A.
To read the full press release, please click here: http://www.fnmprofiles.com/profiles-newc.html
Farmatech S.A. is GMP certified by INVIMA (National Institute of Food & Drug Vigilance) for the production of the following dosage formulations: Solids: Tablets with or without cover, hard gelatin capsules, lozenges, effervescent powders and granules; Semisolid: creams, gels and ointments; Bulk manufacture of suppositories; Liquid solutions, emulsions, and suspensions; and Non lactic antibiotics: Solid powder. In association with Dr. Robert Melamede PhD, President of Cannabis Science Inc., New Colombia will work with Farmatech S.A. to develop products using formulations and processes specific to the ailment being treated. For more information on Farmatech S.A., visit http://www.farmatech.com.
Easton Pharmaceuticals Inc. (OTC Pink: EAPH) recently announced it had provided BMV Medica S.A. de C.V. confirmation of final payment to BMV towards it Mexican initiatives regarding Easton's Viorra product. Announces new Michigan proposal in its medical marijuana initiatives. As previously disclosed, Easton has engaged and announced that BMV Medica S.A. de C.V. has been appointed as its sole exclusive distributor in Mexico. BMV has signed an agreement with Easton on utilizing its resources and relationships aimed at marketing Viorra successfully in a market that BMV believes can be positioned as a leading-edge daily-use woman's health product to also assist in the treatment of FSAD type conditions. Easton has given BMV its approval to launch certain initiatives once manufacturing has been set up in Mexico, currently being addressed by BMV, which when complete, could also supply the United States, Canadian and International markets.
GW Pharmaceuticals plc (NASDAQ: GWPH) recently announced that the Company has received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug application (IND) is now open for Epidiolex in the treatment of Dravet Syndrome, a rare and catastrophic treatment-resistant form of childhood epilepsy. GW expects to commence a Phase 2/3 clinical trial in the second half of 2014. Epidiolex has already received orphan drug designation from the FDA for the treatment of Dravet syndrome. "The acceptance of this IND by the FDA is a significant milestone for Epidiolex and for children with Dravet syndrome for whom existing anti-epileptic medicines often do not provide adequate relief," stated Justin Gover, GW's Chief Executive Officer. "This journey began with requests from the U.S. epilepsy physician and patient community to utilize Epidiolex and has now led to GW embarking on its own formal development program with a view to seeking market authorization from the FDA as rapidly as possible. We are committed to providing a prescription cannabidiol (CBD) medicine for children with Dravet syndrome who have exhausted all other therapeutic options."
Medical Marijuana, Inc. (OTC: MJNA) recently announce that executives from two of its subsidiaries have been recognized as Board of Director nominees by the National Cannabis Industry Association (NCIA). Michael Roberts, Chief Executive Officer of Wellness Managed Services' new company, MPS International (MPSI) and HempMeds(TM) board member, Michael Julian, are both running for election. Online voting is open to NCIA member companies through May 16th at midnight. "The founders of our country, who crafted one of the only constitutions in world history that hasn't been re-written, grew, sold, bought and traded hemp (cannabis) products," states Michael Julian. "Through decades of propaganda, one of the cannabis plants, 'marijuana' has since been added to the list of Schedule I controlled substances. Our legislators are beginning to see just how foolish this is, but more can and should immediately be done to make cannabis ('marijuana' and hemp) completely legal for growth and cultivation in the U.S."
Terra Tech Corp.'s (OTCQB: TRTC) subsidiary, MediFarm LLC, announced it has completed filings for the special use permit process for medical marijuana licensing in unincorporated Clark County, Nevada. In addition, on April 22, 2014, MediFarm LLC filed requisite information with the Clark County Department of Business Licensing for four medical marijuana applications; two Dispensaries, one Cultivation Facility and one Production Facility. MediFarm representatives recently met with the Clark County planning department to file Land Use applications as part of the special use permit process in unincorporated Clark County. The company anticipates that Clark County Commissioners will hear applications for these special use permits on June 5th. "This initial process in Clark County was a tremendous undertaking for our team," explains Derek Peterson, CEO Terra Tech Corp. "As a byproduct of this process we are left with a great base to build our state level applications from. We feel well positioned to submit to the state in a timely manner should we make it through the county's review process. In addition we are focusing on other counties throughout the state."
http://www.prnewswire.com/news-releases/cannabis-based-medicines-gain-traction-as-research--development-ramp-up---company-looks-to-develop-topical-cannabis-medicine-to-treat-skin-cancer-259367381.html

New Colombia Resources Inc. Enters Into a Collaboration Agreement With Farmatech S.A. for Research and Development of Topical Cannabis Based Medicines in Colombia
MIAMI BEACH, Fla., May 15, 2014 /PRNewswire/ --
New Colombia Resources, Inc. (NEWC) ("New Colombia" or "the Company"), a U.S. company with coal and other resource assets in Colombia, is pleased to announce an agreement of collaboration with Farmatech S.A., of Medellin, Colombia, for the research and development of topical cannabis based medicines to treat skin cancer and other ailments in Colombia.
Farmatech S.A. is a pharmaceutical laboratory that collaborates with private companies, universities, institutions and NGOs. Their mission is to manufacture medicines as well as cosmetic and veterinary products, both proprietary and by contract. New Colombia Resources is in discussions with Cannabis Science, Inc. (CBIS) to oversee research in Colombia once the protocols are established by Farmatech S.A.
Farmatech S.A. is GMP certified by INVIMA (National Institute of Food & Drug Vigilance) for the production of the following dosage formulations:
Solids: Tablets with or without cover, hard gelatin capsules, lozenges, effervescent powders and granules.

Semisolid: creams, gels and ointments; bulk manufacture of suppositories.

Liquid solutions, emulsions, and suspensions.

Non lactic antibiotics: Solid powder.

Farmatech S.A. has a manufacturing certificate from INVIMA for cosmetic liquids, creams and gels.
In association with Dr. Robert Melamede PhD, President of Cannabis Science Inc., New Colombia will work with Farmatech S.A. to develop products using formulations and processes specific to the ailment being treated. For more information on Farmatech S.A., visit www.farmatech.com.co.
"Dr. Bob Melamede and I first approached the owners of Farmatech S.A. to research cannabis based formulations in 2010, we all feel now is the right time to develop and market these products. We look forward to collaborating with Cannabis Science Inc, the Phoenix Tears Foundation, and Farmatech S.A. to bring new products to market," stated John Campo, President of New Colombia Resources, Inc.
http://finance.yahoo.com/news/colombia-resources-inc-enters-collaboration-120000289.html

Research & Development Kick Into High Gear For Cannabis Based Medicine - New Collaboration Agreement For Development of Cannabis Based Skin Cancer Medicine
CORAL SPRINGS, Florida, May 9, 2014 /PRNewswire/ --
Marijuana & Cannabinoid Based Medicine industry continues to grow as companies forge ahead searching for new research and development, as well as expansion, opportunities: New Colombia Resources, Inc. NEWC, +16.83% GW Pharmaceuticals plc GWPH, -0.28% Hemp, Inc. HEMP, -2.56% Nuvilex, Inc. NVLX, -3.25% and Tranzbyte Corporation ERBB, +0.00%
New Colombia Resources, Inc. (otcqb:NEWC), a U.S. company with coal and other resource assets in Colombia, is pleased to announce an agreement of collaboration with the Phoenix Tears Foundation for the research and development of a cannabis based medicine to treat skin cancer in Colombia. Dr. Janet Sweeney PhD and Corrie Yelland founders of the Phoenix Tears Foundation have been helping cancer patients with Cannabis based medicines while documenting their research since 2006. New Colombia Resources is also in discussions with Cannabis Science, Inc. (otcqb:CBIS) to oversee clinical trials in Colombia.
The Phoenix Tears Foundation is the namesake of the world famous Phoenix Tears Oil, an extremely potent and sedative cannabis resin with 75-90% THC. They have documented this medicine curing several forms of cancer. The Phoenix Tears Foundation works with Patients Out of Time, a charity dedicated to educating health care professionals and the public about the therapeutic use of cannabis. This organization treats cancer patients in critical need. Most of these patients have no other alternative and have been told by their doctors there is nothing they can do. Within weeks of using the medicine they show remarkable improvement. In many cases the skin cancer is gone within months of using the oil. For more information and testimonials please visit http://www.phoenixtearsfoundation.com
To read the full press release, please click here: http://www.fnmprofiles.com/profiles-newc.html
New Colombia Resources and their scientific advisor, Dr. Robert Melamede PhD, President of Cannabis Science, Inc. (CBIS) are reviewing a proposal from a consulting firm establishing the procedures to begin clinical trials in Colombia. The Company has a clear path of the steps needed to gain an INVIMA approved product. The Company believes the data produced by clinical trials in Colombia can be used to support an FDA IND (Investigative New Drug) application.
GW Pharmaceuticals plc GWPH, -0.28% a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas, NV on Tuesday, 13 May, 2014 at 4:20 p.m. PT (1:20 p.m. ET). The conference will be held at the Encore at Wynn Las Vegas. A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section from the investor's calendar of events page at http://www.gwpharm.com. A replay will be available soon after the live presentation.
Hemp, Inc.'s (otc pink:HEMP) wholly owned subsidiary, The Industrial Hemp and Medical Marijuana Consulting Company, Inc. (IHMMCC), recently announced that it has signed a consultant agreement with Cloud Medical Doctor Software Corporation (Cloud-MD) (NSCT), a leading provider of "Cloud Based" Medical Software solutions and a provider of Digital Electronic Encryption Security solutions (CipherShop) in order to enhance the Industrial Hemp and Medical Marijuana sector's security and inventory management with a new level of professional encryption. The collaboration will allow Cloud-MD to receive and utilize industry-specific consulting services in the area of sales and marketing strategy, press releases, public company venues and general business guidance as the company expands its reach beyond traditional medical software clients into the Industrial Hemp and Medical Marijuana industries. Both Hemp, Inc. and Cloud-MD executives believe Cloud-MD's integrated and interoperable suite of software will become the "Gold Standard" for the industry's need for better cyber security and inventory management.
Nuvilex, Inc. (otcqb:NVLX) recently announced that its advanced pancreatic cancer treatment first outperformed historical data presented by the NYSE's Eli Lilly and its FDA approved pancreatic cancer drug Gemzar®, then it was NASDAQ's Celgene and its recently FDA approved treatment of Abraxane®plus gemcitabine, and now the latest treatment that Nuvilex's Cell-in-a-Box® combined with the anticancer drug ifosfamide outperforms is NASDAQ-listed Merrimack Pharmaceuticals and its treatment, the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin. Between these three biopharmaceutical firms, each has FDA approval or is about to face the FDA seeking approval for an advanced pancreatic cancer treatment. They also represent 3 separate treatments that Nuvilex's Cell-in-a-Box®/ifosfamide combination has produced better data than in two successfully completed Phase I/II clinical trials.
Tranzbyte Corporation (otc pink:ERBB) through the American Green Division together with USEI USEI, +0.00% have signed an agreement to joint venture a grow and dispensary project in the metropolitan Denver region. The project will incorporate USEI's "lighting," American Green's Jurassic water system, and a trial of a top cannabis nutrient product. In addition, the state-approved facility has a recreational dispensary license to be operated by an experienced professional in the business, well known in the market. "It's one thing to talk about our innovative products and quite another thing to ask others to believe in them. This new venture with USEI puts our own skin in the game. We know American Green products work. We also know that USEI's products work. Our combined commitment to improving grow technology is specifically focused on helping to improve the market sector for everyone," says Tranzbyte COO Stephen Shearin.
http://www.marketwatch.com/story/research-development-kick-into-high-gear-for-cannabis-based-medicine-new-collaboration-agreement-for-development-of-cannabis-based-skin-cancer-medicine-2014-05-09

New Colombia Resources, Phoenix Tears Foundation to develop cannabis-based medicine for skin cancer
Published on May 9, 2014 at 9:28 AM
New Colombia Resources, Inc. (OTCQB: NEWC) ("New Colombia or the Company"), a U.S. company with coal and other resource assets in Colombia, is pleased to announce an agreement of collaboration with the Phoenix Tears Foundation for the research and development of a cannabis based medicine to treat skin cancer in Colombia. Dr. Janet Sweeney PhD and Corrie Yelland founders of the Phoenix Tears Foundation have been helping cancer patients with Cannabis based medicines while documenting their research since 2006. New Colombia Resources is also in discussions with Cannabis Science, Inc. (OTCQB: CBIS) to oversee clinical trials in Colombia.
The Phoenix Tears Foundation is the namesake of the world famous Phoenix Tears Oil, an extremely potent and sedative cannabis resin with 75-90% THC. They have documented this medicine curing several forms of cancer. The Phoenix Tears Foundation works with Patients Out of Time, a charity dedicated to educating health care professionals and the public about the therapeutic use of cannabis. This organization treats cancer patients in critical need. Most of these patients have no other alternative and have been told by their doctors there is nothing they can do. Within weeks of using the medicine they show remarkable improvement. In many cases the skin cancer is gone within months of using the oil. For more information and testimonials please visit www.phoenixtearsfoundation.com
"The U.S. federal government, legislators, law enforcement officers and many healthcare professionals often use the "lack of clinical trials" with cannabis as a legitimate reason for continuing the marijuana prohibition. The Catch 22 here is that the federal government has made it virtually impossible for researchers to study the therapeutic efficacy of cannabis. I believe legal clinical trials of Cannabis based medicines in Colombia will not only help Colombian cancer patients but will greatly benefit our efforts in the U.S.," stated Dr. Janet Sweeney PhD, co-founder of the Phoenix Tears Foundation.
New Colombia Resources and their scientific advisor, Dr. Robert Melamede PhD, President of Cannabis Science, Inc. (CBIS) are reviewing a proposal from a consulting firm establishing the procedures to begin clinical trials in Colombia. The Company has a clear path of the steps needed to gain an INVIMA approved product. The Company believes the data produced by clinical trials in Colombia can be used to support an FDA IND (Investigative New Drug) application.
http://www.news-medical.net/news/20140509/New-Colombia-Resources-Phoenix-Tears-Foundation-to-develop-cannabis-based-medicine-for-skin-cancer.aspx

New Colombia Resources Inc. Appoints Dr. Robert Melamede PhD as Scientific Advisor for Research and Approval of Cannabis Based Pharmaceutical Products in Colombia
SUNNY ISLES BEACH, FL -- (Marketwired) -- 04/22/14 --
New Colombia Resources, Inc. (OTCQB: NEWC) ("New Colombia" or "the Company"), a U.S. company with coal and other resource assets in Colombia, is pleased to announce the appointment of Dr. Robert J. Melamede PhD, President of Cannabis Science, Inc., as a scientific advisor to gain approval to legally research and market cannabis based pharmaceutical products in Colombia and other Latin American countries. The Company is discussing a collaborative effort with Cannabis Science, Inc.
Dr. Melamede, retired Chairman of the Biology department of the University of Colorado at Colorado Springs, is a world renowned leader in Cannabis research with many years investigating the human body's endocannabinoid system and its reaction to cannabinoids. Dr. Melamede has made many presentations around the globe explaining the benefits of cannabinoids for cancer patients.
"I am thrilled to finally start this project in Colombia given its history and rising economic standing on the world stage. Many patients in Latin America will benefit from the research done in Colombia," stated Dr. Robert Melamede PhD.
New Colombia Resources will form a joint venture to include U.S. and Colombian investors, universities, and pharmaceutical partners. New Colombia will work closely with government agencies to allow them permission to conduct research of cannabis based formulations. They will hire a reputable law firm to handle government approvals, lobbying, and public relations. The joint venture will conduct studies in different regions of Colombia with high incidences of the specific illness for which treatment is being researched without regard to socio-economic status. New Colombia Resources will lead the effort to gain approval from INVIMA (National Institute of Food & Drug Vigilance) to market these products in Colombia and other Latin American countries.
"Dr. Melamede and I have been discussing research in Colombia for a few years and we feel now is the right time, I'm very happy to work with him again. As a Colombian American I truly believe this is a project of national interest for Colombia. We will make every effort to follow strict international standards in our studies working with universities, research institutions, and pharmaceutical partners throughout Colombia," stated John Campo President of New Colombia Resources, Inc.
The venture will focus its initial efforts on a skin cancer cream and treatments for epilepsy including Dravet syndrome in children. The company will produce a high cannabinoid (CBD) strain low in tetra hydrochloride (THC) similar to the "Charlotte's Web" strain being used in Colorado. Families of children with Dravet Syndrome have been moving to Colorado to legally gain access to these strains and administer it to their children with miraculous results. New Colombia Resources will work with pharmaceutical companies to manufacture products with controlled doses like all INVIMA approved medicines.
Colombia has surpassed Argentina as the third largest economy in Latin America behind Brazil and Mexico. The government of Colombia is injecting US$ 25 Billion into the economy through infrastructure investments in an effort to unleash an economic growth spurt. New Colombia Resources will be a direct beneficiary of these investments by supplying raw building materials for these projects and using the new infrastructure to transport their high quality metallurgical coal to export markets. The Company will provide an update of their rock and coal mining operations in the coming days.
http://www.virtual-strategy.com/2014/04/22/new-colombia-resources-inc-appoints-dr-robert-melamede-phd-scientific-advisor-research-an#axzz3J9BdoHPM

Colombian Research Involving Cannabiods For Cancer Patients & Pharmaceutical Products Heats Up - Company Announces Appointment of Well Known Medical Marijuana Scientific Advisor
CORAL SPRINGS, Florida, April 22, 2014 /PRNewswire/ --
Cannabis advancers making strides in product developments and research events: New Colombia Resources, Inc. NEWC, +16.83% Cannabis Science, Inc. CBIS, +5.60% Medical Marijuana, Inc. MJNA, -4.93% Easton Pharmaceuticals, Inc. EAPH, +7.32% Extreme Biodiesel, Inc. XTRM, +12.90% and Next Generation Energy Corp. NGMC, -6.90%
New Colombia Resources, Inc. (otcqb:NEWC) a U.S. company with coal and other resource assets in Colombia, is pleased to announce the appointment of Dr. Robert J. Melamede PhD, President of Cannabis Science, Inc. (otc pink:CBIS), as a scientific advisor to gain approval to legally research and market cannabis based pharmaceutical products in Colombia and other Latin American countries. The Company is discussing a collaborative effort with Cannabis Science, Inc. Dr. Melamede, retired Chairman of the Biology department of the University of Colorado at Colorado Springs, is a world renowned leader in Cannabis research with many years investigating the human body's endocannabinoid system and its reaction to cannabinoids. Dr. Melamede has made many presentations around the globe explaining the benefits of cannabinoids for cancer patients..
To read the full press release, please click here:http://www.fnmprofiles.com/profiles-newc.html
Dr. Melamede, retired Chairman of the Biology department of the University of Colorado at Colorado Springs, is a world renowned leader in Cannabis research with many years investigating the human body s endocannabinoid system and its reaction to cannabinoids. Dr. Melamede has made many presentations around the globe explaining the benefits of cannabinoids for cancer patients. New Colombia Resources will form a joint venture to include U.S. and Colombian investors, universities, and pharmaceutical partners. New Colombia will work closely with government agencies to allow them permission to conduct research of cannabis based formulations. They will hire a reputable law firm to handle government approvals, lobbying, and public relations. The joint venture will conduct studies in different regions of Colombia with high incidences of the specific illness for which treatment is being researched without regard to socio-economic status
Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting recently announced plans to enter the State of Nevada where new law expands medical cannabis opportunities to research, grows, and dispensaries. As the Company has created a partnership in Michigan to advance state cannabis law and pursue state-wide initiatives in Michigan, Cannabis Science intends to bring its know how and resources to Nevada, the state of Cannabis Science's Incorporation. The new law marks another milestone in the progression in the legalization process of the medical cannabis industry in the United States -- one that is aimed at ways of managing multiple ailments for patients. In addition, the new law is expected to contribute to the creation of new sources of revenue and employment opportunities within the state. Cannabis Science is well positioned to bring novel patient-based initiatives to Nevada.
Medical Marijuana, Inc. (otc pink:MJNA) operates in the medical marijuana and industrial hemp markets. Its products range from patented and proprietary based cannabinoid products to seed and stalk or isolated high value extracts manufactured and formulated for the pharmaceutical, nutraceutical, and cosmeceutical industries. The company's services include development of cannabinoid based health and wellness products; and development of medical grade compounds; and licensing of proprietary testing, genetics, labeling and packaging, tracking, production, and standardization methods for the medicinal herb industry. It also offers pre-and-post production tracking, gemplasm references, and packaging and processing services. On Monday, MJNA closed up 2.33% on over 12.7 million shares traded.
Easton Pharmaceuticals, Inc. (otc pink:EAPH) recently announced that BMV Medica, S.A. de C.V., a Mexican regulatory company and distributor of pharmaceutical products have signed an exclusive agreement to distribute Easton's "VIORRA" product in Mexico. Carla Pepe, CEO of Easton Pharmaceuticals, stated, "BMV Medica, as previously announced, is the company's current regulatory consultant for Mexico and other parts of Latin America. After extensive discussions Easton has finalized a deal whereby BMV Medica will take over Marketing and Distribution for VIORRA." Mrs. Pepe further commented, "They have shown a strong interest in the growth of VIORRA in Mexico, and expect to launch VIORRA later this year, subject to the regulatory approvals and finalizing the sourcing out of a suitable manufacturing partner. Discussions with possible manufacturers are well under way and BMV anticipates finalizing a deal shortly."
Extreme Biodiesel, Inc. (otc pink:XTRM) recently announced the following corporate update to shareholders. The Company has executed a one year lease with one year option on a satellite facility to produce XTRM's Proprietary Mobile Biodiesel Unit / Hemp To Biodiesel Unit. The location of the facility is at 28030 Hwy 74, Lake Elsinore, CA 92570. It houses an office, a working garage, along with the additional space needed for storage of biodiesel equipment. Company President Joseph Spadafore stated "Demand for the Mobile Biodiesel Unit has been decent, we hope that this facility which is within about an hour from the 40 acre project XTRM is developing will help lower the production cost of the unit and result in increased sales."
Next Generation Energy Corp. (otcqb:NGMC) wholly owned subsidiary, NextGen Cannabis Consulting, LLC, recently announced it has retained a prominent California law firm whose varied areas of practice include significant knowledge and background about the medical marijuana industry. NextGen Cannabis has retained the law offices of Ariel Clark to assist it with its business plan to enter the fast growing medical marijuana industry. "We have steadily built a strong management team and industry relationships to aggressively profit from this industry. Exceptional legal talent is equally important to our success and I am extremely pleased to have Ariel Clark and her firm representing NGMC," said Darryl Reed, CEO.
http://www.marketwatch.com/story/colombian-research-involving-cannabiods-for-cancer-patients-pharmaceutical-products-heats-up-company-announces-appointment-of-well-known-medical-marijuana-scientific-advisor-2014-04-22